|
Orchid
forays into anti-AIDS segment
EPP
News Bureau - Mumbai
Orchid
Chemicals and Pharmaceuticals, Chennai based bulk antibiotic drug
manufacturing company is all set to make their presence in the lucrative
anti-AIDS drug business segment. Their anti-AIDS cocktail of four
to five bulk actives is going to hit the market soon. The Drug Controller
of India has already gave the nod for one of its anti-AIDS processes.
According to the deputy managing director of the company Dr C B
Rao their decision to enter the anti-infective market is a part
of its strategic move to add up their value chain by diversifying
their business into non-cephalosporin business, which is its core
area of operation. As they a strong presence in the antibiotic segment
their foray into anti-infectionary business such as anti-AIDS is
supposed to be a clever move.
He said that the company has already got the DCI nod for one of
its processes, Indinavir which is an effective cure for the grave
disease. The company has also developed different processes for
Lamivudine and Ziduvodine and is likely to get the approval from
the DCI.
As the AIDS virus is mutative in nature a single drug is not sufficient
to combat the disease and thus the company is planning to offer
a cocktail of four to five anti-AIDS bulk actives.
According to him Latin America and Africa are the two potential
markets.
|
